Ascentage Pharma Group Inc, located in Rockville, Maryland, operates as a clinical-stage biotechnology company specializing in innovative therapies for cancer, hepatitis B, and age-related diseases. The company focuses on developing inhibitors of protein-protein interactions to effectively restore apoptosis, a crucial process in cell regulation. With a strong portfolio, Ascentage Pharma advances eight drug candidates currently in Phase I or II clinical trials across the U.S., Australia, and China.
The company's research emphasizes breakthrough treatments, particularly targeting pathways critical to cancer progression and resistance. Noteworthy drug candidates include a novel Bcl-2/Bcl-xL inhibitor and therapies aimed at IAP and MDM2-p53 pathways. Ascentage Pharma also explores next-generation tyrosine kinase inhibitors, positioning itself at the forefront of biotechnology innovation.
Ascentage Pharma's commitment to scientific excellence and patient-focused solutions drives its mission to address unmet medical needs. The company's clinical trials reflect a dedication to thorough research and development, ensuring that each candidate undergoes rigorous evaluation for safety and efficacy. This approach fosters confidence in the therapeutic potential of its innovative treatments.
Ascentage Pharma Group Inc delivers essential advancements in the pharmaceutical landscape, contributing significantly to the fight against serious diseases. The focus on protein-protein interactions and groundbreaking therapies showcases the company's strengths and achievements. Connect with Ascentage Pharma in Rockville, Maryland, to explore their innovative solutions.
